MU School of Medicine to Study COVID Treatment that Includes Ivermectin

(Missourinet) The University of Missouri School of Medicine has joined a nationwide to evaluate medications mild-to-moderate COVID-19.  Missourinet’s Joey Parker has details:

MU’s Department of Emergency Medicine is set to examine repurposed medications – meaning meds already approved by the FDA for other conditions.  But the researchers are also looking into the controversial drug Ivermectin, which the FDA says people should not use it to treat or prevent COVID.

MU Health Care Dr. Christopher Sampson says the ACTIV6 clinical trial will keep an open mind.

“So, the current research on Ivermectin does not show a benefit in the treatment of COVID, but the purpose of the ACTIVE6 trial is to alternative medications or what’s called repurposed medications and to see if there actually is a positive effect in treating the illness.”

Researchers say there currently are no approved prescription medications that can be given easily at home to treat mild-to-moderate COVID before it worsens.

MU researchers hope to help change that.

“This study is good in many reasons because it doesn’t require in-person visits, so you don’t necessarily need to be in Columbia to take part it. You just go to the website and register.”

“So, the current research on Ivermectin does not show a benefit in the treatment of COVID, but the purpose of the ACTIVE6 trial is to alternative medications or what’s called repurposed medications and to see if there actually is a positive effect in treating the illness.”

“This study is good in many reasons because it doesn’t require in-person visits, so you don’t necessarily need to be in Columbia to take part it. You just go to the website and register.”